Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2013108272) BLOOD STAGE MALARIA VACCINE
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2013/108272 International Application No.: PCT/IN2013/000041
Publication Date: 25.07.2013 International Filing Date: 21.01.2013
IPC:
A61K 39/00 (2006.01) ,C07K 14/445 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
44
from protozoa
445
Plasmodium
Applicants:
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY [IN/IN]; ICGEB Campus P.O. Box 10504 Aruna Asaf Ali Marg New Delhi 110 067, IN
Inventors:
GAUR, Deepak; IN
CHAUHAN, Virander Singh; IN
CHITNIS, Chetan; IN
Agent:
SUBRAMANIAM, Hariharan; Subramaniam, Nataraj & Associates E- 556, Greater Kailash-II New Delhi 110 048, IN
Priority Data:
177/DEL/201220.01.2012IN
Title (EN) BLOOD STAGE MALARIA VACCINE
(FR) VACCIN ANTIPALUDIQUE CIBLANT LE STADE SANGUIN
Abstract:
(EN) The invention relates to a blood stage malaria vaccine. The vaccine comprises merozite antigens. The merozite antigens are selected from the group consisting of PfF2, PfRHl, PfRH2, PfRH4, PfRH5, AARP and PfMSP-fusion. The vaccine targets merozite surface proteins and the erythrocyte binding domains of multiple parasite adhesins blocking their interaction with their receptors and thus inhibiting erythrocyte invasion. The inventions also provide a method of treatment wherein the antigens block the sialic acid independent as well as sialic acid dependent binding of the parasite P. falciparum to the erythrocyte.
(FR) L'invention concerne un vaccin antipaludique ciblant le stade sanguin. Le vaccin comprend des antigènes de mérozoïtes. Les antigènes de mérozoïtes sont choisis dans le groupe comprenant PfF2, PfRHl, PfRH2, PfRH4, PfRH5, AARP et la fusion de PfMSP. Le vaccin cible des protéines de surface de mérozoïtes et les domaines de liaison des érythrocytes des multiples adhésines parasites bloquant leur interaction avec leurs récepteurs et inhibant ainsi l'invasion des érythrocytes. L'invention concerne également une méthode de traitement selon laquelle les antigènes bloquent l'acide sialique indépendant, ainsi que la liaison dépendant de l'acide sialique de P. falciparum parasite à l'érythrocyte.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)